Hagens Berman filed a lawsuit on behalf of several consumer groups against Solvay Pharmaceuticals claiming that the drug maker had engaged in false and illegal marketing of Estratest, a hormone replacement therapy drug the company had been marketing without FDA approval.
The suit alleged Solvay Pharmaceuticals' marketing materials falsely stated that the hormone replacement therapy drug Estratest worked to treat hot flashes, something the FDA recently began questioning, and implied the drug was approved by the FDA.
Although Solvay applied for approval in 1981, the FDA never approved Estratest for its marketed use.
Several California-based consumer groups supported the suit, including Congress of California Seniors and the California Public Interest Research Group (CALPIRG), along with Boston-based advocacy group Prescription Access Litigation project (PAL).
The case settled for $30 million.

| SHARE: |
|
| Order and Notice of Pendency of Class Action | |
| Long Form Notice | |
| Estratest Complaint | |
| Preliminary Settlement Approval | |
| Solvay Revised Release Form |
| CONTACT US | CYCLING TEAM | TERMS AND CONDITIONS | FIRM BROCHURE | SECURITIES BROCHURE | FOLLOW US ONLINE: |
|
|
|
|

